Summary: Christopher McCabe is Executive Director and CEO of the Institute of Health Economics, and has worked as an academic health economist for over 25 years.
In the 1990s Dr. McCabe worked with local commissioners in the UK NHS evaluating new technologies to inform funding decisions. In the first decade of this century Dr. McCabe worked extensively with the UK National Institute for Health and Care Excellence, (NICE); initially as team leader on the technology appraisal of disease modifying drugs for multiple sclerosis and subsequently as the Founding Director of the NICE Decision Support Unit. He was a member of the writing group for the 2003 Edition of the NICE Guide to the Methods of Technology Appraisal, and an expert advisor to the update published in 2008. Dr. McCabe also served as a member of the NICE Medical Technologies Advisory Committee. In 2007 Dr. McCabe was appointed to the Chair in Health Economics at the University of Leeds, and went on to be the Founding Director of the Academic Unit of Health Economics within the Leeds Institute of Health Science. In 2011 he was appointed to a Capital Health Endowed Research Chair at the University of Alberta, Canada, where he leads two Genome Canada research groups focused on the evaluation, adoption, and implementation of Precision Medicine technologies. Dr. McCabe also served on the Canadian Agency for Drugs and Technologies in Health Care (CADTH) Health Economics Working Group which authored the 4th Edition of the CADTH Guidelines for the Economic Evaluation of Health Technologies in 2017.
Dr. McCabe succeeded Dr. Jonsson as CEO and Executive Director of the Institute of Health Economics in July 2017.
Christopher's recent publications can be found on his Google scholar page